Introduction: With the increasing use of intravitreal administration of corticosteroids in
INTRODUCTION
Diabetic macular edema (DME) is a common complication of diabetes involving the microvasculature of retina. DME is the consequence of a breakdown in the blood-retina barrier which leads to retinal thickening resulting from the accumulation of fluid and exudates [1] . DME is the primary reason of vision loss in diabetic retinopathy, which is a leading cause of blindness in countries with a developed economy [2, 3] .
The goal of therapy in DME is to preserve retinal function by reducing vascular leakage causing edema (expressed as retinal thickening). Laser photocoagulation and intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF), as first line therapy, or corticosteroids, as second line therapy, have demonstrated efficacy [1] . In contrast with anti-VEGFs, which inhibit only the effect of VEGF, corticosteroids have multiple mechanisms of action on various pathways of the inflammatory cascade thus, reducing the effects of VEGF, inflammatory cytokines and other mechanisms involved in the pathogenesis of DME [1] .
With the increasing use of corticosteroids, steroid-induced elevated intraocular pressure (IOP) or ocular hypertension (OHT) are becoming an emergent problem with the reports of incidence ranging from 11% to 79% [4] . The risk of IOP elevation depends on the dose and chemical structure of the steroid, duration of therapy and route of administration [5] . The variable risk according to the route of administration has motivated some authors to evaluate a provocation test before an intravitreal injection. Risk factors for a steroid-induced rise in IOP have been identified: primary open-angle glaucoma (POAG), family history of glaucoma, diabetes, myopia, rheumatoid arthritis, old age or age less than 6 years [5, 6] . However, there are no specific recommendations regarding patient selection and monitoring following intravitreal use of corticosteroids in the setting of diabetic retinopathy. The guidelines of the European Glaucoma Society (EGS) provide recommendations for the management of glaucoma due to corticosteroid treatment, but the common situation of diabetic patients with macular edema being treated with intravitreal corticosteroids is not specifically addressed [5] .
The objective of this article was to review current evidence on steroid-induced IOP elevation and OHT and to provide guidance for the monitoring and management of IOP following treatments with corticosteroids in DME.
METHODS
The authors of this article are an expert panel of
European ophthalmologists who met in Paris in March 2015. The panel's intention was first to review evidence on corticosteroid-induced IOP elevation in DME patients. Since data are sparse or incomplete regarding the specific use of corticosteroids in DME, the panel also considered the relationship between OHT and onset of glaucoma, mechanisms of corticosteroid-induced IOP elevation and current guidelines for the management of corticosteroid-induced IOP elevation.
A monitoring and management algorithm has been proposed that was designed to be acceptable for use across Europe and that can be adapted in local countries. The proposed algorithm is evidence based as far as possible. When necessary, the recommendations were based on panel's experience. This article is intended to be a practical tool for ophthalmologists in the management of corticosteroid-induced IOP elevation. This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS

Intravitreal Corticosteroids Used in DME
The 
Pharmacokinetics of Intravitreal Corticosteroids
Steroids administered in the vitreous are eliminated via two main pathways. The flow of aqueous humor through the anterior chamber angle is the first pathway and the second is posteriorly through the blood-retinal barrier [11, 15] . The concentration of the intravitreal corticosteroids, and consequently its duration of action, depends on the clearance rate from the vitreous [16, 17] . Some authors hypothesized that side effects related to corticosteroids may be explained in part by the differences in drug lipophilicity and partitioning into trabecular meshwork and lens [45] . However, these results have been recently rejected in the scientific literature [46] .
Evidence Base for Elevated IOP After
Corticosteroids in DME
The effects on IOP of intravitreal administration of corticosteroids during large trials for the treatment of DME are summarized in Table 1 .
The results of IOP elevation are, however, difficult to compare since IOP was not a primary endpoint and only reported as an adverse event. Moreover, definitions of IOP were not standardized with different cut-offs for IOP elevation or OHT. Overall, the safety results regarding elevated IOP in patients with DME are similar to those reported in the systematic review of Kiddee et al. which included patients regardless of diabetes status [4] . Nevertheless, a large proportion of patients with DME received IOP-lowering medical treatments and were largely well controlled (Table 1) . Some patients underwent laser trabeculoplasty or incisional glaucoma surgery, but the proportion was low, except for one study of triamcinolone in which 9% underwent glaucoma surgery [47] . Outcomes comparable to those seen in controlled trials were obtained in recent real-world studies [48] [49] [50] [51] . The study of Lam In the panel's opinion, the benefit of a corticosteroid provocation test is equivocal.
Since the great majority of steroid-induced OHT can be managed with medical or laser therapy, a positive steroid challenge does not necessarily imply that a patient would not benefit from intravitreal steroids; the clinician and patient should consider the benefit-risk balance before deciding on the best course of action.
RECOMMENDATIONS
There is no evidence regarding the choice of IOP-lowering treatment or the targeted IOP for steroid-induced OHT in DME patients. The guidelines of the EGS recommend: (1) discontinuation of corticosteroid therapy or switch to weaker steroid; (2) administration of topical or systemic IOP-lowering medication; (3) laser trabeculoplasty and (4) glaucoma surgery in intractable cases [5] . These recommendations are, however, not specific for intravitreal administration, nor for patients with DME. A systematic review by Kiddee addressed the management of IOP but did not discuss the specifics of the diabetic population studied [4] .
We propose two consecutive algorithms for DME patients treated with intravitreal corticosteroids-one for baseline risk stratification (Fig. 1 ) and prior to administering a corticosteroid and the second is for the monitoring and management of IOP after a corticosteroid has been administered (Fig. 2) . In the risk stratification algorithm, patients with pre-existing or advanced glaucoma are not eligible for treatment according to respective package leaflets of fluocinolone acetonide (ILUVIEN) and dexamethasone (Ozurdex) implants [58, 59] ( Fig. 1) . Some authors have suggested that pre-existing glaucoma should be a relative contraindication for steroid use because intravitreal steroids may be the only effective treatment for some patients [6, 56] . The use of intravitreal steroids in such patients would be 'off-label' as the products are not licensed for use in these patients. For monitoring of patients with IOP B21 mmHg, without a history of IOP-lowering medication or IOP increase after In a meta-analysis of randomized controlled trials, the most efficient IOP-lowering drugs were prostaglandins followed by non-selective beta-blockers, alpha-adrenergic agonists, selective beta-blockers and topical carbonic anhydrase inhibitors [60] . However, the panel considered that there were neither particular preferences nor exclusions of specific classes of medical treatment in DME patients with corticosteroid-induced OHT; treatment should start with monotherapy, as set out in the EGS guidelines [5] . The use of prostaglandin analogues is not contraindicated but treating clinicians need to be aware of the uncommon occurrence of macular edema from prostaglandin analogue use [61] .
Contraindications particular to each class of topical anti-glaucoma drugs should be considered on a case-by-case basis [5] .
CONCLUSION
In diabetic patients having intravitreal steroids, clinical studies indicated that the rates of elevated IOP and OHT were comparable with those of non-diabetic patients (for example patients with uveitis). The panel agreed that there is no need for specific management protocol for IOP elevation induced by steroids compared with other causes of raised IOP.
When necessary, IOP-lowering medical treatment or laser trabeculoplasty is sufficient for a large majority of patients and glaucoma surgery is needed for only a small proportion of patients.
These principles have been implemented in an algorithm that is intended to be simple and practical to provide guiding principles to ophthalmologists in the management of corticosteroid-induced IOP elevation. 
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